<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00585936</url>
  </required_header>
  <id_info>
    <org_study_id>Joslin 06-32</org_study_id>
    <secondary_id>P01-A1-054904</secondary_id>
    <nct_id>NCT00585936</nct_id>
  </id_info>
  <brief_title>Imaging Inflammation in Autoimmune Diabetes</brief_title>
  <official_title>Evaluation of Magnetic Nanoparticle Enhanced Imaging in Autoimmune Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AMAG Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether magnetic resonance imaging (MRI) with
      ferumoxtran-10 can be used to detect changes in the pancreas associated with autoimmune
      diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately one million individuals are afflicted with autoimmune Type 1 diabetes mellitus
      (T1DM) in the United States. This disease results from the autoimmune destruction of the
      insulin-producing beta-cells of the islets of Langerhans of the pancreas. Initially, diabetes
      is usually clinically occult with localized pancreatic inflammation characterized by a
      lymphocytic infiltration of the pancreatic islets, termed insulitis, which leads to beta-cell
      specific destruction of the islets. This is often followed by the clinically overt phase that
      ensues when the bulk of beta cells have been destroyed and the pancreas is no longer able to
      produce sufficient insulin to maintain glycemic control. The purpose of this study is to
      assess the ability of magnetic resonance imaging with ferumoxtran-10, a functional molecular
      imaging agent consisting of iron oxide nanoparticles, to detect changes in the pancreas
      associated with the insulitis of T1DM.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>Normal controls without evidence of diabetes or islet specific autoimmunity</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <description>Individuals within 6 months of diagnosis with type 1 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <description>Individuals at high risk for the development of type 1 diabetes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <description>Individuals with longstanding autoimmune diabetes</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population is to be drawn from the general population, diabetes clinic
        population, and at risk individuals as previously identified in prior family studies.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recent onset type 1 diabetes as defined by clinical diagnosis within the last 6 months
             and age less than 30 or at least one islet autoantibody marker (GAD, IAA, or IA-2).

        or

          -  High risk of pre-type 1 diabetes as defined by first degree family relative with type
             1 diabetes and at least one islet autoantibody marker (GAD, IAA, or IA-2).

        or

          -  Individuals with established type 1 diabetes of greater than 6 months duration who
             were under age 30 or at least one islet autoantibody marker positive (GAD, IAA, or
             IA-2) at time of diagnosis or who currently are GAD or IA-2 autoantibody marker
             positive.

        or

          -  Normal control as defined by no family history of type 1 diabetes and normal tolerance
             test (tolerance testing to be performed as part of protocol).

        Exclusion Criteria:

          -  Individuals under 18 years of age

          -  Individuals unable or unwilling to give informed consent/HIPAA authorization

          -  Individuals who are clinically unstable

          -  Individuals with any contraindications to MRI examination, for example, individuals
             with pacemakers

          -  Pregnant or lactating women

          -  Individuals with allergies to iron or dextran

          -  Individuals with a history of cirrhosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard A Jackson, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Turvey SE, Swart E, Denis MC, Mahmood U, Benoist C, Weissleder R, Mathis D. Noninvasive imaging of pancreatic inflammation and its reversal in type 1 diabetes. J Clin Invest. 2005 Sep;115(9):2454-61. Epub 2005 Aug 18.</citation>
    <PMID>16110329</PMID>
  </reference>
  <reference>
    <citation>Denis MC, Mahmood U, Benoist C, Mathis D, Weissleder R. Imaging inflammation of the pancreatic islets in type 1 diabetes. Proc Natl Acad Sci U S A. 2004 Aug 24;101(34):12634-9. Epub 2004 Aug 10.</citation>
    <PMID>15304647</PMID>
  </reference>
  <results_reference>
    <citation>Gaglia JL, Guimaraes AR, Harisinghani M, Turvey SE, Jackson R, Benoist C, Mathis D, Weissleder R. Noninvasive imaging of pancreatic islet inflammation in type 1A diabetes patients. J Clin Invest. 2011 Jan;121(1):442-5. doi: 10.1172/JCI44339. Epub 2010 Dec 1.</citation>
    <PMID>21123946</PMID>
  </results_reference>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2008</study_first_posted>
  <last_update_submitted>November 9, 2011</last_update_submitted>
  <last_update_submitted_qc>November 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 10, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

